Analysis of FDA approved anticancer drugs reveals the future of cancer therapy

Cell Cycle

Volumn 3, Issue 8, 2004, Pages 1033-1040

  Blagosklonny, Mikhail V ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Chemotherapy; FDA; Signal transduction; Targeted agents

Indexed keywords

ALEMTUZUMAB; ARSENIC TRIOXIDE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; RECOMBINANT ALPHA2B INTERFERON; RETINOIC ACID; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; TOSITUMOMAB I 131; TOXOTERE; TRASTUZUMAB; UNINDEXED DRUG; VALRUBICIN; VESONOID;

ABDOMINAL PAIN; ACNE; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; BLADDER CANCER; BLADDER IRRITATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL CYCLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRY SKIN; EDEMA; ELECTROLYTE DISTURBANCE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; INFECTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUSCLE CRAMP; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PROTEINURIA; RASH; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TISSUE SPECIFICITY; VOMITING; WOUND HEALING IMPAIRMENT;

EID: 12844281121     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.8.1023     Document Type: Review

References (84)

1. Broxterman HJ, Georgopapadakou NH. New cancer therapeutics: Target-specific in, cytotoxics out? Drug Resist Updat 2004; 7:79-87.
2. Druker BJ. Imatinib: Paradigm or anomaly? Cell Cycle 2004; 3:833-5.
3. Blagosklonny MV. Gefitinib (Iressa) in oncogene-addictive cancers and therapy for common cancers. Cancer Biol Ther 2004; 3:436-40.
4. Druker BJ, David A. Karnofsky award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 2003; 21:239s-245s.
5. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17:2998-3010.
6. Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: Association with the presence of a secondary transport pathway. Cancer Res 2004; 64:313-39.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44.
8. Folkman J. Tumor angiogenesis: Therapeutic implications. N Eng J Med 1971; 285:1182-6.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
10. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
11. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39.
12. Folkman J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003; 2:5127-33.
13. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5:13-7.
14. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-99.
15. Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: Implications for drug development and practice. Clin Cancer Res 2003; 9:1579-89.
16. Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
17. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004; 3:361-70.
18. Vose JM. Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist 2004; 9:160-72.
19. Riley JK, Sliwkowski MX. CD20: A gene in search of a function. Semin Oncol 2000; 27:17-24.
20. Vose JM. Bexxar: Novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkins lymphoma. Oncologist 2004; 9:160-72.
21. Imai J, Yashiroda H, Maruya M, Yahara I, Tanaka K. Proteasomes and molecular chaperones: Cellular machinery responsible for folding and destruction of unfolded proteins. Cell Cycle 2003; 2:585-90.
22. WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 2000; 14:1276-83.
23. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003; 2:694-9.
24. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM. Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study. J Clin Oncol 2004; 22:115-9.
25. Wilkinson E. Surprise phase III failure for ZD1839. Surprise phase III failure for ZD1839. Lancet Oncol 2002; 3:583.
26. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet 2003; 362:62-4.
27. Blagosklonny MV, Darzynkiewicz Z. Why iressa failed: Toward novel use of kinase inhibitors (outlook). Cancer BiolTher 2003; 2:137-40.
28. CCohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United states food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-8.
29. Herbst RS, Giaccone G, Schiller JH, Nacale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paditaxel and carboplatin in advanced nonsmall-cell lung cancer. A phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-94.
30. Giaccone G, Gonzalez-Larriba JL, van Oosterom AT, Alfonso R, Smit EF, Martens M, Peters GJ, van der Vijgh WJ, Smith R, Averbuch S, Fandi A. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. Ann Oncol 2004; 15:831-8.
31. Baselga J. Combining the anti-EGFR agent gefitinib wich chemotherapy in nonsmall-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 2004; 22:759-61.
32. Haringhuizen A, Van Tinteren H, Vaessen HF, Baas P, Van Zandwijk N. Gefitinib as a last treatment option for nonsmall-ceU lung cancer: Durable disease control in a subset of patients. Ann Oncol 2004; 15:786-92.
33. Pacz JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR Mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39.
35. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 2004; 5:411-5.
36. Weinstein IB. Cancer. Addiction to oncogenes-the achilles heal of cancer. Science 2002; 29:63-4.
37. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: Oxaliplatin. Oncologist 2004; 9:8-12.
38. Haddow A. The influence of carcinogenic substances on sarcomata induced by the same and other compounds. J Pathol Bacteriol 1938; 47:581-91.
39. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, Schilder RJ, Wiseman G, White CA. Durable responses after ibritumomab tiuxetan radio immunotherapy for CD20+ B-Cell lymphoma: Long term follow-up of a phase I/II study. Blood 2004; In press.
40. Countouriotis A, Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002; 20:215-29.
41. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy- refractory peripheral T-cell lymphomas. Blood 2004; 103:2920-4.
42. Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyriakou C, Goldstone AH, Mackinnon S, Hale G. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: Relevance for early adoptive immunotherapy and infectious complications. Blood 2003; 102:404-6.
43. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2:705-13.
44. Antman KH. Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 2001; 6:1-2.
45. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De The H, Wang ZY, Chen SJ, Chen Z. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328-35.
46. Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 2002; 1:201-9.
47. Sordet O, Liao Z, Liu H, Antony S, Stevens EV, Kohlhagen G, Fu H, Pommier Y. Topoisomerase I-DNA complexes contribute to arsenic trioxide-induced apoptosis. J Biol Chem 2004; 279:33968-75.
48. Scheindlin S. More poison from Agatha Christie. N Engl J Med 1994; 331:683.
49. Kwong YL, Todd D. Delicious poison: Arsenic trioxide for the treatment of leukemia. Blood 1997; 89:3487-8.
50. Senior K. Arsenic: Carcinogen or cancer therapy? Drug Discov Today 2002; 7:156-7.
51. van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M, van Dongen JJ. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamidn (Mylotarg®) treatment in acute myeloid leukemia patients. Leukemia 2004; 18:983-8.
52. Sievers EL, Linenberger M. Mylotarg: Antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001; 13:522-7.
53. Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 2004; 100:1213-20.
54. Onrust SV, Lamb HM. Drugs aging. 1999; 15:69-75.
55. Leone F, Perissinotto E, Cavalloni G, Fonsato V, Bruno S, Surrenti N, Hong D, Capaldi A, Geuna M, Piacibello W, Aglietta M. Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. J Leukoc Biol 2003; 74:593-601.
56. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 5:459-65.
57. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart. Semin Oncol 2001; 28:18-26.
58. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125:232-9.
59. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: Comparison with historic data. Cancer 2003; 98:2636-42.
60. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase 1 to inhibit hypoxia inducible factor 1. Cell Cycle 2004; 3:172-5.
61. Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, Parchment RE. Differential toxicity of campcothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol 1997; 39:467-72.
62. Hartman WR, Hentosh P. The antileukemia drug 2-chloro-2′- deoxyadenosine: An intrinsic transcriptional antagonist. Mol Pharmacol 2004; 65:227-34.
63. Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochromec release. Blood 2002; 99:655-63.
64. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980; 77:1561-5.
65. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22:9075-86.
66. 2 cell cycle arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxiclty. Oncogene 2001; 20:3806-13.
67. Blagosklonny MV, Robey R, Sheikh MS, Fojo T. Paclitaxel-induced FasL-independent apoptosis and slow (nonapoptotic) cell death. Cancer Biol Ther 2002; 1:113-7.
68. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332:1004-14.
69. Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10:123-30.
70. Chen JG, Yang CP, Cammer M, Horwitz SB. Gene expression and mitotic exit induced by microtubule-stabilizing drugs. Cancer Res 2003; 63:7891-9.
71. Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, Bates SE. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002; 21:119-27.
72. Cdc2 kinase. Mol Cell 1998; 2:581-91.
73. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96:739-49.
74. Sledge GWJ. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 2003; 17:33-5.
75. Blagosklonny MV, Darzynkiewicz Z. Cyclotherapy: Protection of normal cells and unshielding of cancer cells. Cell Cycle 2002; 1:375-82.
76. Seymour L. Epidermal growth factor receptor inhibitors: An update on their development as cancer therapeutics. Curr Opin Investig Drugs 2003; 4:658-66.
77. Blagosklonny MV. Matching targets for selective cancer therapy. Drug Discov Today 2003; 8:1104-7.
78. Del Bino G, Skierski JS, Darzynkiewicz Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res 1990; 50:5746-50.
79. Halicka HD, Seiter K, Feldman EJ, Traganos F, Mittelman A, Ahmed T, Darzynkiewicz Z. Cell cycle specificity of apoptosis during treatment of leukaemias. Apoptosis 1997; 2:25-39.
80. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Osterborg A. Variability in B-celi antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001; 2:300-6.
81. Mouridsen H, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol 2003; 33-45.
82. Blagosklonny MV. Tissue-selective therapy of cancer. Br J Cancer 2003; 89:1147-51.
83. von Schilling C. Immunotherapy with anti-CD20 compounds. Seminars Cancer Biol 2003; 13:211-22.
84. Cox MC, Figg WD, Thurman PW. No rational theory for drug pricing. J Clin Oncol 2004; 22:962-3.